In the phase 1/2 TRIDENT-1 study (published in January 2024), repotrectinib, which is a next-generation ROS1 inhibitor with activity against G2032R, produced durable responses in ROS1-fusion-positive NSCLC regardless of prior ROS1-TKI exposure [45]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.